Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02837432 · ClinicalTrials.gov registry record · Early Phase 1

The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression

A Early Phase 1 study, sponsored by Stanford University.

Completed
Registry status
Early Phase 1
Development phase
192
Enrollment target

NCT02837432: Completed Early Phase 1 study, sponsored by Stanford University.

NCT02837432 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 192 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (262% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02837432, a Early Phase 1 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Early Phase 1
Development phase
192 participants
Enrollment target

Study Summary

There is good evidence to suggest that the pathological version of sadness that people with Major Depression experience could be caused by the failure of the hormone cortisol to properly inhibit sadness-related brain activity in the subgenual cingulate cortex. This project investigates if the subgenual cingulate cortex has become insensitive to cortisol in patients with depression and tests for variants of the cortisol receptor genes that could predispose individuals to develop cortisol insensitivity.

Interventions

  • DRUG Placebo
  • DRUG Hydrocortisone acetate

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2016-07
Est. Completion 2020-11-15
Phase Early Phase 1
Stanford University

1,744 total trials

What the finished NCT02837432 record still lists

NCT02837432 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (262% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02837432 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02837432 about?

NCT02837432 is a clinical study titled "The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression". There is good evidence to suggest that the pathological version of sadness that people with Major Depression experience could be caused by the failure of the hormone cortisol to properly inhibit sadness-related brain activity in the subgenual cingulate cortex. This project investigates if the subgen...

What is the current status of trial NCT02837432?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 192 participants. The study started on 2016-07. Estimated completion is 2020-11-15.

What interventions are being tested in trial NCT02837432?

The interventions under investigation include: Placebo (DRUG), Hydrocortisone acetate (DRUG).

Who is sponsoring clinical trial NCT02837432?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02837432's enrollment target sits among peer trials

192 71st of 2000 higher than 1,930 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492972 · 192 participants · Phase 3

    Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  • NCT01973881 · 192 participants

    Quantitative MRI for Myelofibrosis

  • NCT02535702 · 192 participants · NA

    Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

  • NCT03622359 · 192 participants · NA

    Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02837432, the US trial registry maintained by the National Library of Medicine. NCT02837432 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.